References
- Brannon-Peppas L, Blanchette JO (2004). Nanoparticle and targeted systems for cancer therapy. Adv Drug Delivery Rev, 56, 1649-59. https://doi.org/10.1016/j.addr.2004.02.014
- Danhier F, Lecouturier N, Vroman B, et al (2009). Paclitaxel-loaded PEGylated PLGA-based nanoparticles: In vitro and in vivo evaluation. J Controlled Release, 133, 11-7. https://doi.org/10.1016/j.jconrel.2008.09.086
- Demeure MJ, Stephan E, Gonzales P, et al (2008). Pre-clinical evidence for nab-paclitaxel efficacy in the treatment of adrenocortical cancer. J Clin Oncol, 26, 22070.
- Desai N, Trieu V, Yao Z, et al (2006). Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res, 12, 1317-24. https://doi.org/10.1158/1078-0432.CCR-05-1634
- Fader AN, Rose PG (2009). Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Int J Gynecol Cancer, 19, 1281-3. https://doi.org/10.1111/IGC.0b013e3181a38e2f
- Gradishar WJ, Tjulandin S, Davidson N, et al (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol, 23, 7794-803. https://doi.org/10.1200/JCO.2005.04.937
- Green MR, Manikhas GM, Orlov S, et al (2006). Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol, 17, 1263-8. https://doi.org/10.1093/annonc/mdl104
- HTTP://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm323668.htm 16.05.2013.
- HTTP://www.has-sante.frportailuploaddocsapplicationpdf2011-01abraxane_ct_7088.pdf 10.02.2013.
- Kratz F (2008). Albumin as drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Controlled Release, 132, 171-83. https://doi.org/10.1016/j.jconrel.2008.05.010
- Lin LY, Karwa A, Kostelc JG, et al (2012). Paclitaxel-loaded SCK nanoparticles: an investigation of loading capacity and cell killing abilities. In Vitro Mol Pharmaceutics, 9, 2248-55. https://doi.org/10.1021/mp3000887
- Saunders DE, Dwayne-Lawrence W, Christensen C, et al (1997). Paclitaxel-induced apoptosis in MCF-7 breast-cancer cells. Int J Cancer, 70, 214-20. https://doi.org/10.1002/(SICI)1097-0215(19970117)70:2<214::AID-IJC13>3.0.CO;2-I
- Sparreboom A, Scripture CD, Treiu V, et al (2005). Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound Paclitaxel (ABI-007) and Paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res, 11, 4136-43. https://doi.org/10.1158/1078-0432.CCR-04-2291
- Topcul M, Cetin I (2013). Nanotechnology in the field of clinical oncology. Marmara Med J, 26, 1-4.
- Wiedenmann N, Valdecanas D, Hunter N, et al (2007). One hundred thirty-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain. Clin Cancer Res, 13, 1868-74. https://doi.org/10.1158/1078-0432.CCR-06-2534
- Yang Y, Niu X, Zhang Q, et al (2010). In vitro inhibiting effect of albumin-bound paclitaxel on human osteosarcoma cell os-732. Shandong Med J, 50, 24-26.
- Yang Y, Niu X, Zhang Q, et al (2012). The efficacy of Abraxane on osteosarcoma xenografts in nude mice and expression of secreted protein, acidic and rich in cysteine. Am J Med Sci, 344, 199-205. https://doi.org/10.1097/MAJ.0b013e31823e62e5
- Zhang C, Awasthi N, Schwartz MA, et al (2013). Superior antitumor activity of nanoparticle albumin- bound Paclitaxel in experimental gastric cancer. Plos One, 8, 1-10.
Cited by
- Clinical Investigation of Efficacy of Albumin Bound Paclitaxel plus Platinum Compounds as First-line Chemotherapy for Stage III/IV Squamous Non-small Cell Lung Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7453
- Development of Polymeric Nanopaclitaxel and Comparison with Free Paclitaxel for Effects on Cell Proliferation of MCF-7 and B16F0 Carcinoma Cells vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2335